Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation...